Alemtuzumab biosimilar (Zhangjiang Biotechnology)

阿仑单抗生物类似药（上海张江生物）

Report date: 2026/04/28 20:00:22

Base Information

Drug NameAlemtuzumab biosimilar (Zhangjiang Biotechnology)

Drug Alias Name阿仑单抗生物仿制药（上海张江生物）重组抗CD52人源化单克隆抗体（上海张江生物）

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCAMPATH-1 antigen inhibitors

TargetsCAMPATH-1 antigen

Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaPending

Originator CompaniesShanghai Zhangjiang Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesShanghai Zhangjiang Biotechnology Co Ltd

Active IndicationsN/A

Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeL04AG06